本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Experts from Various Fields Gather to Discuss Cutting-Edge Medical Topics "Innovation+ Finance" Boosts Development of Medical Startups in Hong KongHONG KONG SAR - Media OutReach Newswire - 16 December 2024 - The Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) and College of Engineering, City University of Hong Kong proudly hosted the inaugural International Cerebro-cardiovascular Medical Innovation Summit (ICMIS) on December 12th. This flagship event brought together leading experts from industry, university, and research sectors to foster cross-disciplinary integration and collaboration among experts, to explore the path of innovation in the healthcare industry. During the summit, COCHE signed an MoU with Shanghai Innovation Bank to establish a partnership focused on fostering medical innovation. MoU Signing Ceremony Bringing Together Leaders from Industry, University and Research The inaugural International Cerebro-Cardiovascular Medical Innovation Summit was held at City University of Hong Kong, featuring prominent representatives from industry, university, and research sectors in the medical field from both Mainland and Hong Kong to explore and drive forward the frontiers of medical innovation. At the opening ceremony, Ms. Gracie NG, Chief of Staff and Acting Chief Corporate Development Officer, HKSTP, Prof. Johnny Chung Yin HO, Associate Vice-President (Enterprise), and Prof. LU Jian, Dean, College of Engineering, City University of Hong Kong, delivered speeches. Ms. Gracie NG said: "The collaboration between COCHE and Shanghai Innovation Bank is of great significance to the bank's business, greatly filling the industry gap in the cooperation between finance and the innovation technology sector. The importance of financial support for the success of startups is also fully reflected in this collaboration. The 'innovation + finance' cooperation model will promote the development of the Hong Kong technology innovation ecosystem." Prof. Johnny Chung Yin HO points: "City University of Hong Kong is the first local university in Hong Kong to promote the concept of 'One Health', in which we established the Institute of Digital Medicine in April of this year. The institute is dedicated to leveraging the university's research strengths in engineering, life sciences, artificial intelligence, and data science to provide innovative digital healthcare solutions. CityU will continue to cultivate more innovation and technology talent through the HK Tech 300 Program and the CityUHK Academy of Innovation, transforming the university's research outcomes into practical applications. Additionally, it will collaborate with the College of Engineering and COCHE to promote innovation and advancements in the healthcare sector. " Prof. LU Jian welcomed the guests on behalf of the summit's co-organizers, in which he mentioned: "The field of engineering plays a crucial role in connecting technological theory with real-world product applications. I am pleased that this summit provides a platform for experts and scholars from various fields to converge, communicate, and collaborate. The summit aims to promote interdisciplinary collaboration, transforming innovative ideas into practical solutions, and dedicate the contribution to the advancement of healthcare outcomes. " Collaboration with Shanghai Innovation Bank to nurture medical innovation During the opening ceremony, COCHE signed an MoU with Shanghai Innovation Bank, establishing a partnership in fostering the "New Quality Productive Forces" through the "innovation + finance" model. The MoU outlines a collaborative framework whereby COCHE will serve as a platform to facilitate the integration of technology innovation resources, including the business matching of relevant startups. This partnership seeks to establish a new win-win cooperation model for innovative enterprise incubation, merging science and technology with finance. Shanghai Innovation Bank will offer tailored debt financing, eco-system connections and various business empowerment initiatives for emerging medical technology startups and support their globalization strategies through collaborative efforts. Prof. Kannie WY CHAN, Centre Director of COCHE, commented: "Funding has always been a significant challenge for the translation of technical solutions into clinical use in Hong Kong. This collaboration provides a much-needed boost to our medical research efforts. By leveraging the 'innovation + finance' model, we can enhance the transformation of research outcomes, generate greater economic benefits, and advance the development of medical new quality productivity forces." Explore Pathways Towards Forward-Thinking Medical Innovation The summit featured two main sessions: "Digital Medical Innovations in Community" and "Ecosystem for Medical Innovations" where experts shared insights and engaged in discussions on a range of topics. Prof. LU Xiongwen, Dean of School of Management at Fudan University, delivered a plenary speech titled "Overview of Empowering Healthcare Enterprises through Management in China and Globally", where he mentioned: "The development of the health industry has enormous demand, and the entire sector is poised for significant growth. Whether in the field of cardiovascular health or the broader health industry, management empowerment is essential. From scientific and technical personnel to product development, and then to industrialization and marketization, the entire process requires management intervention to enable innovation and technological development through effective management. " Prof. Bryan YAN, Head of Division of Cardiology (Academic Affairs) at the Faculty of Medicine of The Chinese University of Hong Kong, delivered a keynote speech on "Stroke Prevention with Innovation". Prof. Bryan YAN highlights innovative strategies, like AI modelling and ECG monitoring for early detection and intervention, that can lead to stroke prevention being greatly enhanced. " By establishing health monitoring systems and raising awareness of risk factors, the goal is to identify individuals at risk of stroke as soon as possible. Integrating these technological solutions can significantly improve prevention efforts, leading to better health outcomes and a lower incidence of strokes." Prof. Bryan YAN said. In addition to serving as a platform for medical and university exchanges, the summit also arranged pitching sessions for different start-up incubated by COCHE to showcase their innovative medical technologies. Among them, Pyrocks Ultrasonics Company mainly produces an AI-Powered Ultrasound Patch for CVD Risk Assessment. This innovation can revolutionize the way people face and manage CVD by screening groups with varying levels of CVD risk, providing timely protection against CVD-related deaths. The inaugural International Cerebro-cardiovascular Medical Innovation Summit (ICMIS) successfully brought together experts, scholars, and industry representatives from various fields to discuss cutting-edge medical topics and promote multi-party collaboration. The summit organizer, COCHE, has taken the lead in the path of cardiovascular and cerebrovascular medical innovation, establishing a partnership with the Board of Directors of Yan Chai Hospital in Hong Kong. Through COCHE's innovative medical technologies and products, health screening activities have been conducted in multiple communities across Hong Kong, enabling residents to become aware of potential health risks in a timely manner. COCHE believes that the future of the healthcare sector relies on interdisciplinary collaboration, and the successful execution of this summit is expected to contribute valuable insights and support for the development of cardiovascular health medicine. Hashtag: #Cerebrocardiovascular#MedicalInnovationSummit #ICMISThe issuer is solely responsible for the content of this announcement.The 1st International Cerebro-cardiovascular Medical Innovation Summit (ICMIS)The International Cerebro-cardiovascular Medical Innovation Summit, a premier gathering of university, clinical, regulatory, industrial, financial, and other diverse fields, featuring leading experts from international realms. This summit aims to serve as a platform for exchange and sharing, fostering dialogue and collaborations among experts across various domains, to explore the path of innovation in the healthcare industry and drive forward the frontiers of medical innovation. Website: https://www.icmis2024.com Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE)In collaboration with the University of Oxford and the Karolinska Institutet, Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) was established under City University of Hong Kong in 2020. The COCHE, supported financially by Innovation and Technology Commission (ITC), was admitted to Inno-Health cluster of InnoHK Programme which is a major R&D initiative of the Hong Kong Special Administrative Region Government. We are developing flexible sensing, biomedical and molecular imaging, nano-biosensing, and AI in health with the focus on innovative wearables that collect key vital signs, including but not limited to continuous blood pressure and electrocardiogram signals on an unobtrusive and real-time basis. The collected data is transmitted for further analysis and integration with other biomarkers, paving the way for the early detection and diagnosis of possible acute cerebro-cardiovascular diseases. Website: https://www.hkcoche.org/
Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy One of the world's most highly endowed medical prizes, with €1 million in prize money, awarded for the first time Titia große Broermann: "With the Broermann Medical Innovation Award, we want to make outstanding medical achievements visible – and honor those who, with courage, vision, and humanity, are shaping the medicine of tomorrow." WIESBADEN, GERMANY - Newsaktuell - 18 November 2025 - At a festive ceremony in the Hessian State Chancellery, Dr. Carl June (University of Pennsylvania) and Dr. Michel Sadelain (Columbia University) were presented with the inaugural Broermann Medical Innovation Award by Minister President Boris Rhein. With a €1 million endowment, the Broermann Award ranks among the world's most prestigious medical honors. Founded by Dr. Bernard große Broermann, the visionary founder of the Asklepios Group, the award recognizes the pioneering achievements of the two scientists in developing CAR-T cell therapy for the treatment of cancer. In the presence of numerous representatives from science, politics, and society, Minister President Rhein honored the work of the award winners and their contribution to the treatment of cancer patients worldwide: "With their work, Dr. Carl June and Dr. Michel Sadelain demonstrate the immense power that knowledge and passion can unleash. They have the potential to positively impact countless lives." The head of government presented the Broermann Prize, worth a total of one million euros — one of the world's most highly endowed awards of its kind praising their "groundbreaking work," saying: "Dr. Carl June and Dr. Michel Sadelain show that knowledge can change lives and give people new hope for healing." He further emphasized "The two prizewinners are inspiring role models through their attitude and dedication. With their insight that the immune system itself can become a weapon against cancer, they have opened a new chapter in cancer therapy." Prof. Dr. Werner Seeger, Chair of the Broermann Award Jury, emphasized: "Today's award ceremony marks a milestone for medical science. Dr. Carl June and Dr. Michel Sadelain have fundamentally transformed cancer treatment through their work on CAR-T cell therapy. Their dedication and pioneering spirit embody the very essence of medical innovation that this award celebrates." Dr. Michel Sadelain, Director of the Columbia Initiative in Cell Engineering and Therapy (CICET), accepted the award on behalf of himself and his colleague Dr. Carl June, Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania. "It is a great honor to receive this recognition together with my colleague Carl June," said Dr. Sadelain. "We are delighted that our decades of work on CAR-T cell therapy are being recognized internationally. This award is both validation and inspiration to continue advancing our research and developing new treatment options for patients with life-threatening diseases. It is a tremendous motivation for our teams and a resolute dedication to bringing better therapies for patients worldwide." Titia Olivia große Broermann, shareholder of the Asklepios Kliniken Group, added: "For me, this award is more than recognition of scientific excellence – it is a living legacy of my husband's vision. Bernard große Broermann believed that health should not be left to fate but can be shaped through innovation and care. Today, scientists like Michel Sadelain and Carl June have made this conviction a reality. Their groundbreaking research has transformed medicine and given countless cancer patients new hope – and, in many cases, a new life. For that, we owe them deep gratitude and great respect." About the Research Dr. Carl June and Dr. Michel Sadelain were honored for their pioneering role in the genetic engineering of T cells to specifically target and destroy cancer cells. Using chimeric antigen receptors (CARs), these modified immune cells can identify cancer cells and eliminate them. CAR-T cell therapies have achieved remarkable success in treating leukemia, lymphoma, and multiple myeloma, opening an entirely new chapter in cancer therapy. About the Laureates Dr. Carl June (born 1950, Denver, USA) received his M.D. from the Baylor College of Medicine, his Ph.D. from the Fred Hutchinson Cancer Research Center, and founded the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania in 1999. He currently holds the Richard W. Vague Professorship in Immunotherapy. Dr. Michel Sadelain (born 1960, Paris, France) earned his M.D. from the University of Paris in 1984 and his Ph.D. from the University of Alberta in 1989. After postdoctoral research at the Whitehead Institute for Biomedical Research (MIT), he joined the Memorial Sloan Kettering Cancer Center in New York in 1994. He now leads the Columbia Initiative in Cell Engineering and Therapy (CICET), founded in 2024. Pictures from the award ceremony will be available shortly after the event at the following website: https://www.broermann-award.org/press/ Broermann Medical Innovation Award Contact: Corinna Larsen Tel.: +49 (0) 641 / 985-42302 E-mail: contact@broermann-award.org Visit Broermann Medical Innovation Award online and on social media: www.broermann-award.com www.facebook.com/people/Broermann-Medical-Innovation-Award/61567211302915/ www.linkedin.com/company/broermann-medical-innovation-award/ www.mastodon.social/@BroermannMedicalnnovationAward www.instagram.com/broermannaward Asklepios Kliniken Coroporate Communications Marketing Department Tel.: +49 (0) 40 / 18 18-82 66 36 E-mail: presse@asklepios.com 24—hour press-office on-call service: +49 (0) 40 / 1818-82 8888 Visit Asklepios online and on social media: www.asklepios.com www.asklepios.com/gesundheitsmagazin http://www.youtube.com/asklepioskliniken de.linkedin.com/company/asklepios www.instagram.com/asklepioskliniken/ www.facebook.com/asklepioskliniken The issuer is solely responsible for the content of this announcement.About the Broermann Medical Innovation AwardThe Broermann Medical Innovation Award was established in 2024 by Dr. Bernard große Broermann, founder of the Asklepios Kliniken. Guided by his vision to create a healthcare organization that delivers real benefit to patients through innovation, Asklepios became a pioneer in medical technology and digital healthcare solutions. The award continues his legacy, honoring those whose groundbreaking work improves lives and shapes the future of medicine. Call for Nominations – 2026 Award The nomination phase for the Broermann Medical Innovation Award 2026 is now open. Nominations of scientists who have made pioneering contributions to medicine, biotechnology, or related disciplines are welcome until March 1, 2026. Further details on eligibility and selection criteria are available on the award's official website.
HONG KONG SAR - Media OutReach Newswire – 11 September 2024 - The Hong Kong Polytechnic University (PolyU) today signed a collaboration agreement with Suzhou Kowloon Hospital, a subsidiary of the Hong Kong Kowloon Group, to jointly establish the "Suzhou Kowloon Hospital – The Hong Kong Polytechnic University Innovation Incubation Platform". The two institutions will leverage their respective strengths, sharing resources over the next three years to promote the translation and application of medical technology research outcomes. This will help drive innovation and clinical application research in the field and enhance the development and quality of the healthcare industry, enabling patients to enjoy better treatment and service. PolyU and Suzhou Kowloon Hospital signed a collaboration agreement to develop the “Suzhou Kowloon Hospital – The Hong Kong Polytechnic University Innovation Incubation Platform”. Witnessed by Dr Lawrence Li (left, back row), Deputy Council Chairman of PolyU, and Mr Hei Sun (right, back row), Chairman of the Hong Kong Kowloon Group, the agreement was signed by Prof. Christopher Chao (left, front row), Vice President (Research and Innovation) of PolyU, and Mr Qiang Chen (right, front row), Vice President of the Hong Kong Kowloon Group. PolyU is committed to promoting PolyImpact through excellence in education, research and knowledge. Leveraging its innovative inventions, the University also aims to translate research outcomes into practical solutions that benefit society. Focused on developing a new medical and healthcare services platform, Suzhou Kowloon Hospital aspires to promote comprehensive application and improvement of medical products. Witnessed by Dr Lawrence LI, Deputy Council Chairman of PolyU, and Mr Hei SUN, Chairman of the Hong Kong Kowloon Group, the agreement was signed by Prof. Christopher CHAO, Vice President (Research and Innovation) of PolyU, and Mr Qiang CHEN, Vice President of the Hong Kong Kowloon Group. Under this agreement, PolyU and Suzhou Kowloon Hospital will strengthen their collaboration in accelerating research and clinical application in areas including medical engineering and artificial intelligence to foster innovation and translation in medical technology. To this end, a biomedical technology innovation incubator will be established, whereby Suzhou Kowloon Hospital will consolidate its extensive clinical resources to support PolyU research teams and startups in developing novel medical products, ensuring their application across multiple scenarios. In addition, the two institutions will initiate various clinical application research projects, leveraging PolyU's robust research capabilities and the clinical experience of Suzhou Kowloon Hospital expert team. Their collaboration aims to facilitate technological enhancements and validate clinical efficacy and safety. PolyU students will be provided with internships, field visits and professional exchange opportunities to enrich their understanding of medical engineering and information technology in clinical practice. Relevant PolyU departments and faculties will also provide professional medical practitioners with tailored study programmes and industry training to foster talent development. Dr Lawrence Li, Deputy Council Chairman of PolyU remarked, "PolyU is pleased to collaborate with Suzhou Kowloon Hospital to establish the 'Suzhou Kowloon Hospital – The Hong Kong Polytechnic University Innovation Incubation Platform', marking another milestone in the University's research and entrepreneurship development. As the University's first clinical incubation platform, it not only provides research teams with clinical support, but also enables our startups to accelerate the translation of research outcomes into clinical applications. At PolyU, we are committed to cultivating an innovative entrepreneurial spirit through the PolyVentures ecosystem by offering comprehensive support to startups. This partnership will reinforce this ecosystem and nurture next-generation entrepreneurs." Mr Hei Sun, Chairman of the Hong Kong Kowloon Group said, "Through this close collaboration, we will create an innovative platform which provides integrated support for R&D, incubation and acceleration to promote knowledge transfer and technological exchange. This is a pioneering initiative that facilitates medical and industrial collaboration for leveraging complementary advantages and synergy. It also provides young entrepreneurs and researchers with an opportunity to showcase their talent, and provides a new engine to help drive technology transfer and industry transformation across Hong Kong, the Greater Bay Area, the Yangtze River Delta and the Asia Pacific region more broadly." Following the signing ceremony, a panel discussion was held with the participation of PolyU academics, experts from Suzhou Kowloon Hospital and representatives from Mainland medical technology companies. Discussion was themed around the topic "Building Collaborative Ecosystems: How Universities, Hospitals and the Healthcare Industry Can Collaborate to Spur Innovation" and addressed some of the challenges faced by the industry, and explored strategies to strengthen organisational cooperation to drive industry growth. Hashtag: #PolyUThe issuer is solely responsible for the content of this announcement.About The Hong Kong Polytechnic UniversityThe Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university with a strong sense of social responsibility, driven by its motto, "To learn and to apply, for the benefit of mankind". The University provides the best holistic education to nurture socially responsible "leaders of tomorrow" who possess a strong sense of national identity and a global perspective, and pursues impactful innovation and interdisciplinary research to address the world's most pressing challenges. A robust culture of knowledge transfer and entrepreneurship is a cornerstone of the University, ensuring PolyU's technologies are transformed into practical real-world applications. The University's unwavering commitment to excellence has earned it international recognition, with PolyU consistently ranking among the top 100 universities worldwide. Based on this solid foundation, the University will continue to make positive contributions in collaboration with its strategic partners for the betterment of Hong Kong, the Nation, and the world. About Suzhou Kowloon Hospital of The Hong Kong Kowloon GroupThe Hong Kong Kowloon Group is a prominent healthcare organisation that seamlessly integrates medical, research, education, rehabilitation and nursing services. Over the years, the Group has proactively aligned itself with the Nation's development strategy, leveraging initiatives such as "Healthy China 2030", the integrated development of the Yangtze River Delta and the China-Singapore Suzhou Industrial Park which serves as a national pilot free trade zone. With an accumulated investment of RMB 5 billion, the Group has been instrumental in fostering the healthcare industry in Suzhou, establishing a comprehensive life cycle healthcare service platform. Notable medical institutions within the Group's portfolio include Suzhou Kowloon Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Suzhou Heiwa Maternity Hospital, and Suzhou Dushu Lake Hospital. Suzhou Kowloon Hospital stands out as the first non-public tertiary care hospital in Jiangsu Province, boasting a distinguished team of medical experts, with approximately 53% of its physicians holding doctoral or master's degrees. The hospital houses 48 clinical medical technology laboratories, academician workstations, and renowned doctor studios. Currently staffed with nearly 2,000 medical professionals, the hospital provides exceptional care to over 1.5 million patients annually and conducts more than 25,000 surgeries.
CYBERJAYA, Malaysia, Aug. 28, 2025 /PRNewswire/ -- Futurise Sdn Bhd (Futurise), in collaboration with the Medical Device Authority (MDA), hosted the latest edition of RegTalk at the Siemens Healthineers Experience Center, focusing on "AI Medical Devices in Malaysia – Balancing Innovation & Safety." Panelists sharing their expertise during the RegTalk session held in Kuala Lumpur The session brought together regulators, industry leaders, and policy experts to explore the opportunities and challenges of artificial intelligence in healthcare. The discussion highlighted the critical balance between fostering innovation and ensuring patient safety, clinical validation and ethical data use. Shafinaz Salim, Acting CEO of Futurise, delivered the welcome address, underscoring Malaysia's pivotal moment in digital health. "The convergence of AI and medical technology presents extraordinary opportunities from predictive diagnostics to real-time patient monitoring. Yet, these advancements also introduce new complexities that must be navigated carefully especially when it comes to public safety, clinical validation, and ethical data use," said Shafinaz. She also announced plans to collaborate with MDA in establishing Malaysia's first regulatory sandbox for medical devices. "This proposed regulatory sandbox is more than a testing mechanism. It is a strategic platform to accelerate responsible innovation, by allowing innovators to safely trial AI-driven medical technologies within a controlled environment under the oversight of MDA. Our aim is clear and that is to support industry growth while safeguarding public health, in full alignment with MDA's mandate," she added. Shafinaz further emphasised the importance of enabling innovation through progressive regulatory frameworks. "To achieve this vision, we must address a crucial challenge: regulation. Innovation thrives in environments that allow experimentation, and this is where regulatory sandboxes can play a transformative role. The sandbox framework allows industries to experiment with new ideas without the immediate constraints of existing regulations, enabling rapid prototyping and faster scaling. As Futurise is mandated by the Government to drive the National Regulatory Sandbox, we believe the regulatory sandbox is the perfect enabler and plays a crucial role in this." A regulatory sandbox for medical devices would allow Malaysia to pilot and validate AI-driven medical technologies in a risk-managed environment, enable regulatory bodies to observe and respond to real-time challenges, build confidence among innovators, clinicians, and the public, and ultimately fast-track the adoption of safe, patient-centric innovations into the healthcare ecosystem. The keynote was delivered by Aidahwaty M. Olaybal, Senior Director of the Pre-Market Control Division, Medical Device Authority (MDA), who emphasised the importance of regulatory frameworks in ensuring innovation is aligned with patient safety and trust. She highlighted that as AI-driven technologies continue to evolve, regulatory oversight must remain adaptive and forward-looking to address emerging risks. Aidahwaty also stressed that collaboration between regulators, industry, and healthcare professionals is essential to build a resilient ecosystem that balances innovation with public confidence. "Striking the right balance between innovation and safety requires centring collaboration, bringing together developers, clinicians, ethicists, and regulators in a shared space of co-creation. It also demands rigorous real-world validation, beyond lab environments, to ensure AI devices perform reliably in diverse clinical settings. Regulatory sandboxes offer the ideal environment to test and iterate safely. And importantly, education must remain continuous for developers, users, and decision-makers alike, so that we evolve alongside our technology," said Aidahwaty. The panel discussion was moderated by Deepak Pillai, Partner at Christopher & Lee Ong Malaysia, and featured Idamazura Idris @ Harun, Senior Director of the Policy and Strategic Planning Division at the Medical Device Authority (MDA), Dr. Ylu-Cho Chung, Head of Research Collaboration at Siemens Healthcare Singapore, and Ella Al-Hakim, Associate at Asia Group Advisors. The panel explored key issues such as regulatory harmonisation, international best practices, ethical considerations in AI deployment, and strategies to accelerate the adoption of AI-powered medical devices responsibly. The event reaffirmed the importance of public-private collaboration to ensure Malaysia strengthens its position as a leader in digital health innovation, while maintaining the highest standards of safety and trust. Looking ahead, Futurise highlighted that building an enabling ecosystem will require active participation from stakeholders across the healthcare value chain including regulators, clinicians, innovators, investors, and patients. By fostering open dialogue, knowledge-sharing, and capacity-building, Malaysia can establish a strong foundation for AI-driven medical technologies to thrive. Futurise remains committed to advancing a safe and progressive digital health ecosystem. By working hand-in-hand with government and industry partners, the organisation aims to shape a regulatory landscape that not only empowers businesses and drives innovation, but also positions Malaysia as a leader in global digital health and industrial growth. As Futurise and MDA move forward with the development of the regulatory sandbox framework, the priority will be to align innovation with patient-centric outcomes, ensuring that Malaysia's healthcare system remains both progressive and trustworthy in the age of artificial intelligence. This outcome of RegTalk 2025 sets the stage for a broader roadmap where regulatory sandboxes will serve as a key mechanism to test and refine breakthrough innovations in a structured environment, supporting Malaysia's ambitions in digital health while contributing to ASEAN's collective effort in shaping safe and sustainable healthcare solutions powered by technology. For more information, please visit www.futurise.com.my. About Futurise Futurise is a wholly-owned subsidiary of Cyberview Sdn Bhd under the Ministry of Finance. It is mandated by the Government of Malaysia to manage the National Regulatory Sandbox, providing public policy advisory and acting as a key enabler of regulatory solutions to expedite innovation and future-proof Malaysia's economy. About Medical Device Authority (MDA) MDA is the government agency entrusted to serve the Malaysia medical device industry. It is a federal statutory agency under the Ministry of Health Malaysia to implement and enforce the Medical Device Act 2012 (Act 737). The main objectives of the Act are to address public health and safety issues related to medical devices and to facilitate medical device trade and industry. Follow Futurise social media for updates: FB: https://www.facebook.com/futurisemy/Instagram: https://www.instagram.com/futurisemyLinkedin: https://www.linkedin.com/company/futurise/Twitter: https://twitter.com/FuturiseMY
SINGAPORE, April 11, 2025 /PRNewswire/ -- Duke-NUS Medical School has appointed Professor Patrick Tan as its next and fourth Dean, effective 1 January 2026, marking a new chapter for the School as it builds on its legacy of medical education, research and innovation. Prof Tan will serve as Dean-designate from 1 July 2025, succeeding Professor Thomas Coffman, the School's longest-serving Dean since 2015. This leadership transition coincides with the School's 20th anniversary, underscoring Duke-NUS' commitment to advancing the future of healthcare in Singapore and the region. Professor Patrick Tan appointed as Duke-NUS Dean to lead next era of medical innovation and education An internationally recognised cancer geneticist and clinician-scientist, Prof Tan is currently Senior Vice-Dean for Research at Duke-NUS, where he leads transformative research initiatives in genomics, precision medicine and biomedical innovation. He was one of the School's pioneer faculty members and has been involved in advancing its research strategy. Prof Tan has also been an active contributor in Singapore's research landscape, taking on roles including Executive Director of Precision Health Research Singapore (PRECISE), Senior Scientific Advisor at SingHealth and former Executive Director of the Genome Institute of Singapore. His leadership in integrating cutting-edge science with clinical applications has placed him at the forefront of Singapore's biomedical ecosystem. A firm believer in team science, Prof Tan is passionate about fostering interdisciplinary collaborations to solve Singapore's most pressing healthcare challenges. His ability to drive impactful change was recognised with the Exemplary Leader Award at the 2023 Public Sector Transformation Award Ceremony. Other awards include the President's Science Award (Team), American Association for Cancer Research (AACR) Team Science Award, and election to the American Society of Clinical Investigation and Association of American Physicians. A strong endorsement from Duke and NUS leadership Professor Tan Eng Chye, President of the National University of Singapore (NUS), said:"After a rigorous search within the University and globally, Patrick has been identified as the best candidate to lead Duke-NUS into its next chapter of growth as a key pillar in Singapore's healthcare and biomedical ecosystem. Patrick brings remarkable visionary leadership and profound expertise through years of dedicated service and contributions as researcher, scientist and educator. I am confident that his leadership and wealth of knowledge will bring the School towards higher levels of excellence, ensuring that our next generation of doctors, researchers and healthcare leaders are well-prepared to meet the challenges of tomorrow." Mr Goh Yew Lin, Chairman of the Duke-NUS Governing Board, said:"Patrick is first and foremost a world-class researcher, but what sets him apart is his deep understanding of how discovery and education must go hand in hand. As a graduate-entry medical school, Duke-NUS trains future clinicians who are not only skilled in patient care but also capable of asking bold questions and driving innovation. As Dean, he will ensure that the School's research priorities remain aligned with our national Research, Innovation and Enterprise (RIE) strategy, while strengthening translation and partnerships that attract industry collaborators and nurture a culture of innovation among our students." Professor Mary Klotman, MD, Executive Vice President for Health Affairs at Duke University, Dean of Duke University School of Medicine, and Chief Academic Officer of Duke Health, welcomed Prof Tan's appointment:"We are excited to work with Patrick as he takes on the mantle of the next Dean of Duke-NUS. A distinguished scientist and strategic leader, he brings a clear vision for how cutting-edge research and meaningful education can converge to improve lives. His commitment to collaboration and academic excellence makes him well-positioned to lead Duke-NUS into its next phase—strengthening our global partnership and expanding the School's contributions to advance health for all." The joint search committee to identify the successor for the role of Dean was chaired by Professor Aaron Thean, Deputy President (Academic Affairs) and Provost of the National University of Singapore, as well as Deputy Chairman of Duke-NUS Governing Board; and included faculty members from Duke-NUS, NUS, Duke University, SingHealth and the Duke-NUS Governing Board. Professor Tan's Vision for Duke-NUS Reflecting on his appointment, Professor Patrick Tan shared:"The healthcare landscape is evolving rapidly, driven by shifting demographics, intensifying demands on healthcare, and technological innovations. These are major challenges, but they also create huge opportunities. As Dean, I look forward to enhancing our long-standing Academic Medicine partnership with SingHealth and harnessing the collective strengths of Duke University and NUS, our parent institutions, to deepen our understanding of diseases and advancing medical solutions that will make a real difference to patients. "By combining the power of cutting-edge research, medical education and translational innovation, Duke-NUS is uniquely positioned to shape the future of medicine. Together with our valued partners, I am immensely grateful for the opportunity to work with our faculty, students, alumni and stakeholders to build on this strong foundation and drive the School's next stage of development in Singapore and the world." Honouring a Decade of Leadership: Professor Thomas Coffman Duke-NUS also expresses deep gratitude to Professor Thomas Coffman for his exceptional leadership over the past decade. A renowned physician-scientist in nephrology and cardiovascular research, Prof Coffman strengthened Duke-NUS' education and research landscape, ensuring that its training programmes remain rigorous and responsive to Singapore's evolving healthcare needs. He founded and built up the School's Cardiovascular and Metabolic Disorders Signature Research Programme as Director. Under his leadership, Duke-NUS also secured strategic funding to advance key research initiatives and played a critical role in Singapore's COVID-19 response, contributing to innovations such as rapid immune response testing. Prof Klotman expressed her appreciation for outgoing Dean, Prof Coffman, adding:"Tom has been an extraordinary bridge between Duke and Duke-NUS, deepening the ties between our institutions and reinforcing the values we share—academic excellence, collaboration and impact. Under his steady and visionary leadership, Duke-NUS has flourished as a beacon of innovation in education, research and clinical care. His legacy is not only reflected in the School's achievements but in the strength of our transcontinental partnership and global contributions to biomedical science." Mr Goh also expressed appreciation to outgoing Dean, Prof Coffman, saying:"Tom has led Duke-NUS through a defining decade with wisdom, vigour and steady resolve. He has not only guided the School's academic and research growth, but also shaped a culture that prizes excellence, collaboration and innovation. We are deeply grateful for his contributions and leadership, which have laid a strong foundation for the next chapter." Even as he steps down from his role as Dean, Prof Coffman will continue to lead key research initiatives, including DYNAMO, a multi-institutional study focussed on reducing the prevalence of diabetic kidney disease in Singapore and around the world. ### About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit www.duke-nus.edu.sg
To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank Planning to initiate global multinational clinical projects in digital therapeutics Establishing a future medical system centered around prevention and management... Expanding digital medical services SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- Amid growing concerns about a medical crisis as a result of acute conflict between the government and the medical community due to an increase in the quota of medical school admission, the regular seminar of the Korea Medical Innovation Research Forum (KMIRF) kicked off; experts from various fields of the medical field gathered to prepare for future medical reform. It was held at Andaz Seoul Gangnam on the 17th of April. First ‘Korea Medical Innovation Research Forum’ regular seminar KMIRF was launched last March by experts in various fields of the medical industry, and is co-represented by Dae Hee Kang, former dean of Seoul National University College of Medicine, current president of the Telemedicine Society, and Jong Yoon Lim, former chairman of the Bio Association, registered director of Hanmi Science and chairman of COREE Group. Medical experts who serve as steering and working committee members of each division, including co-representatives Dae Hee Kang and Jong Yoon Lim, gathered and led a heated discussion for medical reform. In addition, the newly elected People Power Party Representatives Cheolsoo Ahn, Soomin Park, and Democratic Party Representative Do-geol Ahn (via video conference) attended and advocated the Forum at the National Assembly level. Co-representative Jong Yoon Lim mentioned the urgency of addressing immediate medical reform in his opening speech and said, "Medical intellectual property rights belong to the country and the people, and in order to improve the country's global competitiveness and future value in medicine, we need to go beyond Healthcare 4.0 and create a national and permanent proposition." "We will definitely propose future medical innovation policies," he said. "We plan to hold regular seminars for KMIRF at least six times a year and frequently put forward future medical innovation policies with the cooperation of experts and policymakers in each field." In his congratulatory address, Rep. Cheolsoo Ahn said, "The paradigm of health care has completely changed through COVID-19, and now, as part of medical reform, we need to establish a 'future-oriented legal system' that recognizes upcoming technological and social changes, and eliminates regulations that may become obstacles in advance." He emphasized, "It is time to play a role in preparing ahead for the future," and added, "I hope that KMIRF will be play a central role for this change." Co-representative Dae Hee Kang emphasized the importance and revitalization of digital healthcare and personalized preventive medicine through a presentation on the topic of 'Future Medicine and Digital Healthcare', as well as laying out the purpose and role in the establishment of KMIRF along with future goals. He also explained the operation plan and said, "We plan to register as an official research group within the National Assembly Secretariat and will fulfill our role as Korea's representative medical think tank." Industrial Division Director Mahn Soon Hwang gave a presentation on 'Bio-Industry Trends' and emphasized the importance of the country, companies, and investments for the development of the bio-ecosystem and medical reform. In addition, a free discussion was commenced in relation to digital health, especially digital therapeutics, as with new therapeutics. It was suggested that regulatory bodies should be able to determine the price and fee structure that will compensate private companies for their enormous investment in clinical research at the time of approval, and came to a consensus that the tone should be set globally in which any country applying for clinical trials or regulatory approval should be adequately recompensed according to such profit structure logic. As the first step in accomplishing this vision, we have decided to pursue a project regarding multi-national digital therapeutics' clinical trials around the world. Hee Hwang, CEO of Kakao Healthcare, expressed his encouragement by saying that he deems it as a very timely strategy and said, "As a healthcare expert, I will utilize my expertise to help with the research group's first project." Hong Taek Yong, a professor at Hanyang University (former 1st Vice Minister of Science and Technology), said, "I am looking forward to the role of Hanyang University at a time when innovative policies need to be promoted in order to incorporate the remarkable advancements in science and technology into healthcare, and I will do my best to contribute as a member." Professor In Taek Lim of Catholic University (former Director of the Health and Medical Policy Office of the Ministry of Health and Welfare) said, "In order to effectively respond to the rapidly changing medical environment and technological changes, our medical system must develop into human-centered digital-based medical care, and the launch of KMIRF at this time is critical." "We will strive to ensure that the research committee stands at the center of this," he said. Meanwhile, the KMIRF aims to create a healthcare ecosystem where the government, medical community, companies, and citizens can coexist, establishing a future healthcare system centered around prevention and management, and resolving intergenerational and regional medical service imbalances through digital medicine, and other platforms. It will be a proponent in presenting ways to expand access to medical services. In addition, it plans to serve as a bridge through which medical policymakers and decision-makers can come together to commonly recognize and empathize with the all related policies that are put forth. KMIRF is comprised of policy, human resources, and industry divisions; while Hong Taek Yong, former 1st Vice Minister of Science and ICT, leads the policy division, Yu Mi Seo, former 11th director of the Korea Education and Research Information Service, heads the human resources division, and Mahn Soon Hwang, current CEO of Korea Investment Partners leads the industrial division. First ‘Korea Medical Innovation Research Forum’ regular seminar First ‘Korea Medical Innovation Research Forum’ regular seminar [Appendix] Korea Medical Innovation Research Forum Steering Committee Name Profile Dae Hee Kang Former Dean of Seoul National University College of Medicine / Current President of the Telemedicine Society Jong Yoon Lim Former Chairman of the Bio Association / Current Chairman of COREE Group / Current Internal Director of Hanmi Science Hong Taek Yong Former First Vice Minister of Science and ICT / Current Professor at Hanyang University In Taek Lim Former Director of Health and Medical Policy, Ministry of Health and Welfare / Current Research Professor, Graduate School of Health and Medical Management, Catholic University of Korea Oh Sang Kwon Former Deputy Director of the Ministry of Food and Drug Safety / Current Visiting Professor at Seoul National University Kil Won Kim Current President of Korea Medical Biotechnology Association Yu Mi Seo Former 11th Director of Korea Education and Research Information Service Jong Il Kim Current Dean of Department of Medical Sciences, Seoul National University Yoo Suk Hong Current Dean of College of Engineering, Seoul National University Mahn Soon Hwang Current CEO of Korea Investment Partners Sung Kwan Jung Current Medical Vice Chairman of the Korean Hospital Association / Chairman of the Board of Directors of Our Children's Hospital, Our Children's Medical Foundation Byung Ho Nam Former Professor at Boston University / Current CEO of Herings, Co. Ltd. Hee Hwang Current CEO of Kakao Healthcare Young Shin Lee Current CEO of Seers Technology Sung Jun Han Current CEO of Avixgen, CTO of Dx&Vx
A12 藝術空間
medical innovation
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
